BioTime, Inc. (BTX) Lifted to Hold at Zacks Investment Research

BioTime, Inc. (NYSEMKT:BTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

A number of other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of BioTime from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine downgraded shares of BioTime from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $6.50 price target (up from $6.00) on shares of BioTime in a research note on Monday, June 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.33.

BioTime (BTX) traded down 1.06% on Tuesday, reaching $2.81. 256,120 shares of the company’s stock traded hands. The firm has a market capitalization of $325.41 million, a PE ratio of 4.72 and a beta of 1.37. The firm’s 50 day moving average price is $2.81 and its 200 day moving average price is $3.02. BioTime has a 52-week low of $2.47 and a 52-week high of $3.96.

TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/10/biotime-inc-btx-lifted-to-hold-at-zacks-investment-research.html.

In other news, Director Broadwood Partners, L.P. bought 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average price of $2.60 per share, with a total value of $26,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have purchased 173,896 shares of company stock valued at $481,220.

Large investors have recently modified their holdings of the business. Voya Investment Management LLC increased its stake in BioTime by 38.3% in the second quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 8,996 shares in the last quarter. American International Group Inc. increased its stake in BioTime by 8.3% in the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 3,036 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in BioTime in the second quarter valued at approximately $142,000. Nationwide Fund Advisors increased its stake in BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 939 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in BioTime by 25.2% in the second quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 10,000 shares in the last quarter.

According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

A number of other equities research analysts also recently weighed in on the stock. BidaskClub downgraded shares of BioTime from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine downgraded shares of BioTime from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $6.50 price target (up from $6.00) on shares of BioTime in a research note on Monday, June 19th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $5.33.

BioTime (BTX) traded down 1.06% on Tuesday, reaching $2.81. 256,120 shares of the company’s stock traded hands. The firm has a market capitalization of $325.41 million, a PE ratio of 4.72 and a beta of 1.37. The firm’s 50 day moving average price is $2.81 and its 200 day moving average price is $3.02. BioTime has a 52-week low of $2.47 and a 52-week high of $3.96.

TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/10/biotime-inc-btx-lifted-to-hold-at-zacks-investment-research.html.

In other news, Director Broadwood Partners, L.P. bought 10,000 shares of the stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average price of $2.60 per share, with a total value of $26,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have purchased 173,896 shares of company stock valued at $481,220.

Large investors have recently modified their holdings of the business. Voya Investment Management LLC increased its stake in BioTime by 38.3% in the second quarter. Voya Investment Management LLC now owns 32,496 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 8,996 shares in the last quarter. American International Group Inc. increased its stake in BioTime by 8.3% in the first quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 3,036 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in BioTime in the second quarter valued at approximately $142,000. Nationwide Fund Advisors increased its stake in BioTime by 2.2% in the first quarter. Nationwide Fund Advisors now owns 44,578 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 939 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in BioTime by 25.2% in the second quarter. Moors & Cabot Inc. now owns 49,630 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 10,000 shares in the last quarter.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with MarketBeat.com's FREE daily email newsletter.